Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia Read more about Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia
Information on the total number of voting rights and shares Read more about Information on the total number of voting rights and shares
Bone Therapeutics reports half year 2020 results Read more about Bone Therapeutics reports half year 2020 results
Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region Read more about Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region
Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study Read more about Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study
Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020 Read more about Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020
Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 8 February 2021 Read more about Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 8 February 2021
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study Read more about Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
Bone Therapeutics and Rigenerand sign partnership for cell therapy process development Read more about Bone Therapeutics and Rigenerand sign partnership for cell therapy process development
Bone Therapeutics provides fourth quarter 2020 business update and 2021 outlook Read more about Bone Therapeutics provides fourth quarter 2020 business update and 2021 outlook
